Eli Lilly Investigates How Liver Function Affects New Drug LY3437943

Understanding how a new drug is processed by the body, known as pharmacokinetics (PK), is crucial for determining safe and effective dosing. This is especially important for individuals with hepatic impairment (liver dysfunction), as their ability to metabolize and eliminate drugs can be significantly altered, leading to potential drug accumulation or reduced efficacy. This Phase 1 study specifically aimed to characterize the PK profile of the investigational drug LY3437943 across various degrees of liver function, from healthy to severely impaired, to inform future dosing strategies.

While specific quantitative results from this completed study are not detailed in the abstract, the primary objective was to determine how LY3437943 behaves pharmacokinetically in individuals with varying degrees of hepatic impairment. The study aimed to quantify key PK parameters such as Cmax (maximum concentration), AUC (area under the curve, total drug exposure), and t1/2 (half-life) for LY3437943 in each group. > The findings are expected to reveal whether liver dysfunction significantly alters the systemic exposure or elimination rate of LY3437943, potentially indicating a need for dose adjustments in patients with impaired liver function. Specifically, the study would have identified if LY3437943 exposure increased by a significant factor (e.g., 2-fold or 3-fold) in patients with moderate or severe impairment compared to healthy controls. Furthermore, the safety and tolerability profile across these groups would have been assessed, looking for any increased incidence of adverse events in participants with compromised liver function.